SNPHY
Santen Pharmaceutical Co., Ltd. [SNPHY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SNPHY Stock Summary
In the News
SNPHY Financial details
Company Rating
Strong Buy
Market Cap
3.43B
Income
27.73B
Revenue
302.08B
Book val./share
844.74
Cash/share
235.72
Dividend
-
Dividend %
-
Employees
4.14K
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
19.87
Forward P/E
-
PEG
16.6
P/S
1.8
P/B
1.71
P/C
0.04
P/FCF
16.32
Quick Ratio
1.97
Current Ratio
2.66
Debt / Equity
0.11
LT Debt / Equity
0.11
-
-
EPS (TTM)
76.22
EPS next Y
-
EPS next Q
-
EPS this Y
-156.68%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
3.58%
Revenue Q/Q
4.92%
EPS Q/Q
-15.73%
-
-
-
-
SMA20
-4.78%
SMA50
-5.92%
SMA100
4.11%
Inst Own
0%
Inst Trans
0.98%
ROA
6%
ROE
9%
ROC
0.12%
Gross Margin
61%
Oper. Margin
14%
Profit Margin
9%
Payout
46%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.71-10.8
52W High
-7.7%
52W Low
+31.86%
RSI
43.06
Rel Volume
0.42
Avg Volume
5.33K
Volume
2.24K
Perf Week
-0.86%
Perf Month
-11.93%
Perf Quarter
-
Perf Half Y
3.71%
-
-
-
-
Beta
0.264
-
-
Volatility
0.14%, 0.33%
Prev Close
-2.12%
Price
9.23
Change
-1.18%
SNPHY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 576.18 | 605.16 | 624.86 | 666.02 | 720.24 | |
| Net income per share | 78.67 | 59.17 | 17.1 | 68.08 | -38.58 | |
| Operating cash flow per share | 80.99 | 100.08 | 97.15 | 115.17 | 95.88 | |
| Free cash flow per share | 60.47 | 76.96 | 37.56 | 25.52 | 32.42 | |
| Cash per share | 174.96 | 230.19 | 158.75 | 210.89 | 151.46 | |
| Book value per share | 716.21 | 758.76 | 770.01 | 844.19 | 758.81 | |
| Tangible book value per share | 341.61 | 402.31 | 418.86 | 482.55 | 489.4 | |
| Share holders equity per share | 716.21 | 758.76 | 770.01 | 844.19 | 758.81 | |
| Interest debt per share | 17.1 | 25.26 | 17.02 | 69.67 | 84.54 | |
| Market cap | 686.95B | 726.72B | 613.16B | 488.91B | 436.58B | |
| Enterprise value | 620.22B | 647.62B | 560.42B | 438.83B | 414.88B | |
| P/E ratio | 21.5 | 30.77 | 89.77 | 17.96 | -29.21 | |
| Price to sales ratio | 2.94 | 3.01 | 2.46 | 1.84 | 1.56 | |
| POCF ratio | 20.88 | 18.19 | 15.8 | 10.62 | 11.75 | |
| PFCF ratio | 27.97 | 23.66 | 40.87 | 47.92 | 34.76 | |
| P/B Ratio | 2.36 | 2.4 | 1.99 | 1.45 | 1.49 | |
| PTB ratio | 2.36 | 2.4 | 1.99 | 1.45 | 1.49 | |
| EV to sales | 2.65 | 2.68 | 2.25 | 1.65 | 1.49 | |
| Enterprise value over EBITDA | 10.89 | 12.68 | 18.27 | 8.14 | 32.04 | |
| EV to operating cash flow | 18.86 | 16.21 | 14.44 | 9.53 | 11.17 | |
| EV to free cash flow | 25.25 | 21.08 | 37.35 | 43.01 | 33.03 | |
| Earnings yield | 0.05 | 0.03 | 0.01 | 0.06 | -0.03 | |
| Free cash flow yield | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 | |
| Debt to equity | 0.01 | 0.03 | 0.02 | 0.08 | 0.11 | |
| Debt to assets | 0.01 | 0.02 | 0.01 | 0.06 | 0.07 | |
| Net debt to EBITDA | -1.17 | -1.55 | -1.72 | -0.93 | -1.68 | |
| Current ratio | 3.21 | 3.23 | 2.63 | 2.39 | 2.38 | |
| Interest coverage | 15.65 | 14.01 | 8.68 | 29.68 | -2.06 | |
| Income quality | 1.03 | 1.84 | 5.84 | 1.69 | -2.48 | |
| Dividend Yield | 0.02 | 0.01 | 0.02 | 0.02 | 0.03 | |
| Payout ratio | 0.33 | 0.44 | 1.64 | 0.44 | -0.84 | |
| Sales general and administrative to revenue | 0.3 | 0.3 | 0.32 | 0.32 | 0.34 | |
| Research and developement to revenue | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Intangibles to total assets | 0.34 | 0.29 | 0.28 | 0.28 | 0.23 | |
| Capex to operating cash flow | -0.25 | -0.23 | -0.61 | -0.78 | -0.66 | |
| Capex to revenue | -0.04 | -0.04 | -0.1 | -0.13 | -0.09 | |
| Capex to depreciation | -0.76 | -0.56 | -1.42 | -2.1 | -1.43 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.13K | 1.01K | 544.27 | 1.14K | 811.63 | |
| ROIC | 0.11 | 0.07 | 0.02 | 0.07 | -0.02 | |
| Return on tangible assets | 0.12 | 0.08 | 0.02 | 0.08 | -0.05 | |
| Graham Net | 131.79 | 171.77 | 152.44 | 136.17 | 79.73 | |
| Working capital | 134.08B | 150.96B | 127.68B | 133.61B | 123.82B | |
| Tangible asset value | 161.46B | 182.71B | 194.17B | 206.63B | 196.99B | |
| Net current asset value | 96.13B | 112.35B | 110.93B | 106.29B | 85.44B | |
| Invested capital | 0.01 | 0.03 | 0.02 | 0.08 | 0.11 | |
| Average receivables | 81.64B | 85.81B | 91.5B | 97.79B | 103.41B | |
| Average payables | 30.91B | 32.33B | 35.34B | 39.65B | 43.07B | |
| Average inventory | 32.94B | 35.26B | 38.43B | 39.36B | 38.25B | |
| Days sales outstanding | 131.97 | 131.46 | 140.37 | 136.52 | 140.26 | |
| Days payables outstanding | 129 | 125.39 | 141.61 | 137.07 | 145.24 | |
| Days of inventory on hand | 141.69 | 135.8 | 154.5 | 123.61 | 127.17 | |
| Receivables turnover | 2.77 | 2.78 | 2.6 | 2.67 | 2.6 | |
| Payables turnover | 2.83 | 2.91 | 2.58 | 2.66 | 2.51 | |
| Inventory turnover | 2.58 | 2.69 | 2.36 | 2.95 | 2.87 | |
| ROE | 0.11 | 0.08 | 0.02 | 0.08 | -0.05 | |
| Capex per share | -20.52 | -23.12 | -59.59 | -89.65 | -63.47 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 183.83 | 210.2 | 194.19 | 203.68 | 217.82 | |
| Net income per share | 15.5 | 2.96 | 27.94 | 24.6 | 20.73 | |
| Operating cash flow per share | 26.32 | 22.99 | 6.82 | 69.88 | 89.67 | |
| Free cash flow per share | 14.04 | 12.57 | -1.05 | 63.61 | 85.07 | |
| Cash per share | 161.65 | 155.63 | 126.33 | 184.1 | 235.72 | |
| Book value per share | 780.57 | 779.73 | 807.25 | 852.23 | 844.74 | |
| Tangible book value per share | 517.88 | 502.89 | 544.92 | 587.1 | 584.02 | |
| Share holders equity per share | 780.57 | 779.73 | 807.25 | 852.23 | 844.74 | |
| Interest debt per share | 99.14 | 84.99 | 93.51 | 95.4 | 97.07 | |
| Market cap | 404.58B | 424.86B | 455.52B | 492.62B | 489.97B | |
| Enterprise value | 380.45B | 403.17B | 444.7B | 461.79B | 441.56B | |
| P/E ratio | 16.92 | 95.18 | 10.94 | 13.89 | 16.71 | |
| Price to sales ratio | 5.71 | 5.36 | 6.29 | 6.71 | 6.36 | |
| POCF ratio | 39.87 | 49.02 | 179.06 | 19.56 | 15.45 | |
| PFCF ratio | 74.76 | 89.65 | -1.16K | 21.48 | 16.29 | |
| P/B Ratio | 1.34 | 1.45 | 1.51 | 1.6 | 1.64 | |
| PTB ratio | 1.34 | 1.45 | 1.51 | 1.6 | 1.64 | |
| EV to sales | 5.37 | 5.09 | 6.14 | 6.29 | 5.73 | |
| Enterprise value over EBITDA | 29.82 | 37.72 | 26.06 | 27.83 | 29.69 | |
| EV to operating cash flow | 37.49 | 46.52 | 174.8 | 18.33 | 13.93 | |
| EV to free cash flow | 70.3 | 85.07 | -1.13K | 20.14 | 14.68 | |
| Earnings yield | 0.01 | 0 | 0.02 | 0.02 | 0.01 | |
| Free cash flow yield | 0.01 | 0.01 | 0 | 0.05 | 0.06 | |
| Debt to equity | 0.12 | 0.11 | 0.12 | 0.11 | 0.11 | |
| Debt to assets | 0.09 | 0.07 | 0.08 | 0.08 | 0.08 | |
| Net debt to EBITDA | -1.89 | -2.03 | -0.63 | -1.86 | -3.25 | |
| Current ratio | 2.73 | 2.38 | 2.67 | 2.66 | 2.46 | |
| Interest coverage | 7.89 | 8.93 | 75.89 | 25.41 | 15.73 | |
| Income quality | 1.71 | 7.84 | 0.24 | 2.84 | 4.34 | |
| Dividend Yield | 0.02 | 0 | 0.01 | 0 | 0.01 | |
| Payout ratio | 1.02 | 0.09 | 0.57 | 0.01 | 0.79 | |
| Sales general and administrative to revenue | 0.33 | 0.39 | 0.29 | 0.3 | 0.28 | |
| Research and developement to revenue | 0.1 | 0.08 | 0.09 | 0.08 | 0.07 | |
| Intangibles to total assets | 0.24 | 0.23 | 0.23 | 0.22 | 0.21 | |
| Capex to operating cash flow | -0.47 | -0.45 | -1.15 | -0.09 | -0.05 | |
| Capex to revenue | -0.07 | -0.05 | -0.04 | -0.03 | -0.02 | |
| Capex to depreciation | -1.15 | -0.96 | -0.73 | -0.46 | -0.35 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 521.81 | 227.88 | 712.32 | 686.77 | 627.76 | |
| ROIC | 0.02 | 0 | 0.03 | 0.03 | 0.03 | |
| Return on tangible assets | 0.02 | 0 | 0.03 | 0.03 | 0.02 | |
| Graham Net | 84.55 | 81.93 | 79.87 | 107.44 | 115.06 | |
| Working capital | 129.85B | 123.82B | 127.07B | 134.89B | 133.17B | |
| Tangible asset value | 199.65B | 196.99B | 203.14B | 211.62B | 206.52B | |
| Net current asset value | 84.91B | 85.44B | 86.96B | 95.45B | 94.77B | |
| Invested capital | 0.12 | 0.11 | 0.12 | 0.11 | 0.11 | |
| Average receivables | 91.51B | 101.28B | 105.53B | 98.66B | 89.21B | |
| Average payables | 39.38B | 43.27B | 43.14B | 42.6B | 44.5B | |
| Average inventory | 38.21B | 38.33B | 40.79B | 43.9B | 46.25B | |
| Days sales outstanding | 121.07 | 121.77 | 129.09 | 114.6 | 99.25 | |
| Days payables outstanding | 126.68 | 147.09 | 123.89 | 134.18 | 126.33 | |
| Days of inventory on hand | 113.64 | 128.78 | 126.58 | 139.35 | 131.38 | |
| Receivables turnover | 0.74 | 0.74 | 0.7 | 0.79 | 0.91 | |
| Payables turnover | 0.71 | 0.61 | 0.73 | 0.67 | 0.71 | |
| Inventory turnover | 0.79 | 0.7 | 0.71 | 0.65 | 0.69 | |
| ROE | 0.02 | 0 | 0.03 | 0.03 | 0.02 | |
| Capex per share | -12.28 | -10.42 | -7.88 | -6.26 | -4.59 |
SNPHY Frequently Asked Questions
What is Santen Pharmaceutical Co., Ltd. stock symbol ?
Santen Pharmaceutical Co., Ltd. is a JP stock and trading under the symbol SNPHY
What is Santen Pharmaceutical Co., Ltd. stock quote today ?
Santen Pharmaceutical Co., Ltd. stock price is $9.23 today.
Is Santen Pharmaceutical Co., Ltd. stock public?
Yes, Santen Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 5.33K
- Market Capitalization 3.43B
- Employee 4.14K
- CEO Mr. Takeshi Ito
- Headquarters Osaka,JP
- IPO Date 2011-08-31
-
Website
https://www.santen.com 
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
